-
1
-
2
-
3
-
4
Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus
Published 2023“…They have demonstrated1 that empagliflozin treatment resulted in a significant decrease in pulse pressure (PP), mean arterial pressure (MAP) and cardiac workload, compared with placebo; at week 12, placebo-adjusted mean changes from baseline were − 2.5 mmHg for PP, − 2.2 mmHg for MAP and − 315 mmHg x beats per minute (bpm) for cardiac workload (p < 0.0001 for all). …”
Get full text
Get full text
Get full text
-
5
CLINICAL AND ECONOMIC IMPACT OF GENETIC AND NON-GENETIC FACTORS ON INR NORMALIZATION IN PRE-OPERATIVE MANAGEMENT OF WARFARIN PATIENTS
Published 2021“…The economic evaluation of the above practice demonstrated that the mean overall cost of peri-procedural warfarin management per patient was USD 3,260 (QAR 11,900), associated with an overall success rate of 0.752. …”
Get full text
-
6
Epidemiology of herpes simplex virus type 2 in Europe: systematic review, meta-analyses, and meta-regressions
Published 2023“…Seroprevalence decreased by 1% per calendar year. Pooled mean proportions of HSV-2 detection in GUD and in genital herpes were 22.0% (95% CI: 15.3–29.6%) and 66.0% (95% CI: 62.9–69.1%), respectively. …”
Get full text
Get full text
Get full text
-
7